Arthneeti
RB

Rossari Biotech

Q4 FY26Chemicals & Petrochemicals

Rossari Biotech Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹499
Market cap₹2.8K Cr
P/E18.4
Updated24 Aug 2026
Read5 min read

The short version

Targeting a minimum 15% growth in FY27 driven by expansions in agro, pharma, personal care, and textile exports (including markets like Bangladesh, Thailand, Turkey, and Brazil). The company expects a minimum of 15% revenue growth in FY27 driven by expansion in personal care, agro, textile exports, and animal health and nutrition (AHN) segments.

From Rossari Biotech's Q4 FY26 earnings-call transcript · updated 24 Aug 2026.

Revenue & Sales Performance

  • Targeting a minimum 15% growth in FY27 driven by expansions in agro, pharma, personal care, and textile exports (including markets like Bangladesh, Thailand, Turkey, and Brazil).
  • New premix facility in Animal Health Nutrition (AHN) expected to ramp up revenues starting FY27, supporting growth.
  • CAPEX of Rs. 50-70 crore planned for FY27 focused on pharma and aroma chemical facilities to support value-added product segments.
  • Growth expected over the next 2-3 years through new customer additions and expansion in high-margin segments such as pharma, oil and gas, aroma, personal care, food processing, and institutional chemicals.
  • Core B2B businesses to drive growth with latent growth in Agro, Textile, AHN, and Personal Care.
  • Export growth anticipated to outperform domestic textile growth, supported by product approvals and expanding global footprint.
  • Plans to divest non-core, lower-margin consumer businesses to improve focus and profitability in core segments.

Profitability & Margins

See what Rossari Biotech said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY27 CAPEX plan is Rs. 50 crore to Rs. 75 crore, including:
  • - New pharma facility expansion
  • - Aroma chemical facility expansion
  • Earlier large CAPEX plans (Rs. 190 crore across multiple sites) have been rephased due to market conditions; some parts postponed to optimize cash flow and returns
  • New R&D facility set up in Navi Mumbai consolidating existing operations, supporting faster innovation and scale-up
  • Ethoxylation capacity expanded to 66,000 metric tons per annum at Dahej, improving supply reliability
  • Ongoing focus on capacity utilization and operational efficiencies to support growth
  • Some capital spending to continue on high-margin segments like pharma and aroma chemicals, with careful optimization to manage cash flows and improve ROCE
  • No specific timeline given for some smaller CAPEX and pilot projects; plans will be phased over FY27 and possibly FY28

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

5x potential
1Shiv Texchem
Rev 1Mar 2
2Yasho Industries
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Rossari Biotech said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript on page 19 and surrounding pages does not explicitly mention specific details about the current or expected order book or pending orders in quantified terms. However, relevant points related to demand and order pipeline include: - Utilization levels for ethoxylation capacity are very high (90%-100%), running continuously, indicating strong order demand. - The company sees a good pipeline of projects across its sales and business development teams worked on in the last 12 months. - No demand-side challenges reported despite raw material price increases; orders remain robust. - Growth drivers include North America for personal care and agro businesses, ramping up exports in textiles through Bangladesh, Southeast Asia, Thailand, Turkey, and Brazil. - New premix facility at AHN starting revenues this quarter is expected to contribute significantly. - Institutional business expected to break even or become profitable by FY27 due to divestment of low-margin segments. Overall, the company signals confidence in a strong order pipeline and continued growth.

Rossari Biotech — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹685 Cr, net profit ₹46 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Rossari Biotech Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • NOCIL Ltd (Q4 FY26)

    The Rs.130 crores capex includes some intermediates and is largely for captive consumption, with part allocated to finished goods. Key concall takeaways from…

  • Indo Borax & Chemicals Ltd (Q4 FY26)

    175 crores revenue in the previous financial year and Rs. Key concall takeaways from Indo Borax & Chemicals Ltd's Q4 FY26 earnings call — and how it ranks…

  • Pidilite Industries Ltd (Q4 FY26)

    Underlying volume growth (UVG) averaged over 9% per quarter last year, with a ~200 bps increase in FY '25; the company plans to continue lifting UVG…

  • PCBL Chemical Ltd (Q4 FY26)

    The company has reduced overall borrowings by approximately INR 450 crores in the current year. Key concall takeaways from PCBL Chemical's Q4 FY26 earnings…

Compare:vs Solar Industries India Ltdvs Pidilite Industries Ltdvs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Rossari Biotech Q4 FY26 results?

Targeting a minimum 15% growth in FY27 driven by expansions in agro, pharma, personal care, and textile exports (including markets like Bangladesh, Thailand, Turkey, and Brazil). The company expects a minimum of 15% revenue growth in FY27 driven by expansion in personal care, agro, textile exports, and animal health and nutrition (AHN) segments.

What is Rossari Biotech share price analysis?

Rossari Biotech currently shows a neutral. The stock trades at a P/E of 18.4 with a market cap of ₹2,779 Cr. Investors should review the full earnings analysis for detailed insights.

Is Rossari Biotech planning capital expenditure?

FY27 CAPEX plan is Rs.

Keep Rossari Biotech on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.